Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Angiodynamic Inc (NASDAQ: ANGO) was $10.92 for the day, down -4.55% from the previous closing price of $11.44. In other words, the price has decreased by -$4.55 from its previous closing price. On the day, 1.69 million shares were traded. ANGO stock price reached its highest trading level at $11.4488 during the session, while it also had its lowest trading level at $10.62.
Ratios:
Our analysis of ANGO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.33 and its Current Ratio is at 2.24. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In the most recent recommendation for this company, Lake Street on July 16, 2025, initiated with a Buy rating and assigned the stock a target price of $24.
On April 05, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $12.
On September 25, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $19.H.C. Wainwright initiated its Buy rating on September 25, 2023, with a $19 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 21 ’25 when Weiss Lawrence T bought 10,000 shares for $11.81 per share. The transaction valued at 118,100 led to the insider holds 93,597 shares of the business.
Trowbridge Stephen A bought 890 shares of ANGO for $9,932 on Oct 13 ’25. The EVP and CFO now owns 256,629 shares after completing the transaction at $11.16 per share. On Oct 09 ’25, another insider, Clemmer James C, who serves as the President and CEO of the company, bought 10,000 shares for $11.15 each. As a result, the insider paid 111,500 and bolstered with 882,529 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ANGO now has a Market Capitalization of 450093824 and an Enterprise Value of 412000640. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.46 while its Price-to-Book (P/B) ratio in mrq is 2.57. Its current Enterprise Value per Revenue stands at 1.341 whereas that against EBITDA is 2157.071.
Stock Price History:
The Beta on a monthly basis for ANGO is 0.51, which has changed by -0.06991869 over the last 52 weeks, in comparison to a change of 0.19182634 over the same period for the S&P500. Over the past 52 weeks, ANGO has reached a high of $13.99, while it has fallen to a 52-week low of $8.27. The 50-Day Moving Average of the stock is -13.42%, while the 200-Day Moving Average is calculated to be 2.93%.
Shares Statistics:
ANGO traded an average of 498.80K shares per day over the past three months and 642360 shares per day over the past ten days. A total of 41.57M shares are outstanding, with a floating share count of 38.85M. Insiders hold about 5.70% of the company’s shares, while institutions hold 95.61% stake in the company. Shares short for ANGO as of 1765756800 were 2121460 with a Short Ratio of 4.25, compared to 1763078400 on 2174768. Therefore, it implies a Short% of Shares Outstanding of 2121460 and a Short% of Float of 5.48.
Earnings Estimates
The market rating of Angiodynamic Inc (ANGO) is currently shaped by the ongoing analysis conducted by 2.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.06 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.26 and -$0.33 for the fiscal current year, implying an average EPS of -$0.29. EPS for the following year is -$0.12, with 2.0 analysts recommending between -$0.12 and -$0.13.
Revenue Estimates
It is expected that $90B in revenue will be generated in . The current quarter, according to 3 analysts. It ranges from a high estimate of $78M to a low estimate of $75.3M. As of . The current estimate, Angiodynamic Inc’s year-ago sales were $72MFor the next quarter, 3 analysts are estimating revenue of $80.97M. There is a high estimate of $82.5M for the next quarter, whereas the lowest estimate is $79.9M.
A total of 3 analysts have provided revenue estimates for ANGO’s current fiscal year. The highest revenue estimate was $313.64M, while the lowest revenue estimate was $312M, resulting in an average revenue estimate of $312.88M. In the same quarter a year ago, actual revenue was $292.5MBased on 3 analysts’ estimates, the company’s revenue will be $328.33M in the next fiscal year. The high estimate is $330M and the low estimate is $326M.
